Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926516 | 0.88 | POLB (0.60) | CNR1SMN1; SMN2KMT2APOLBLMNA | |
| SCHEMBL9926585 | 0.76 | P2RX7 (0.50) | SMN1; SMN2KMT2AP2RX7POLBLMNA | |
| SCHEMBL9926517 | 0.74 | ALDH1A1 (0.66) | SMN1; SMN2POLBLMNA | |
| SCHEMBL20772369 | 0.74 | CNR1 (0.47) | CNR1GAASMN1; SMN2KMT2ATP53 | |
| SCHEMBL9926646 | 0.73 | P2RX7 (0.48) | KMT2ATP53MAPTP2RX7HDAC2 | |
| SCHEMBL9926532 | 0.73 | HTT (0.54) | SMN1; SMN2KMT2ATP53P2RX7POLB | |
| Hydrochloric Acid SCHEMBL22320782 | 0.73 | SMN1; SMN2 (0.47) | CNR1GAASMN1; SMN2KMT2ATP53 | |
| Hydrochloric Acid SCHEMBL30553806 | 0.73 | SMN1; SMN2 (0.47) | CNR1GAASMN1; SMN2KMT2ATP53 | |
| SCHEMBL26099449 | 0.72 | CDK1 (0.58) | CNR1KMT2AHDAC2HDAC8HDAC6 | |
| SCHEMBL9926586 | 0.72 | HPGD (0.50) | SMN1; SMN2KMT2ATP53MAPTP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | CNR1 2104/4885GAA 2555/4885SMN1; SMN2 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.